CBD is just the tip of the cannabinoid iceberg

Press enter to search
Close search
Open Menu

CBD is just the tip of the cannabinoid iceberg

By Ryan Lewis, Global Cannabinoids - 01/03/2020

Currently, the hemp industry is experiencing an explosion of interest in the cannabinoid of the moment, cannabidiol, or CBD. It is fast becoming the trendiest ingredient across multiple channels from nutraceutical and skin care to animal health and sports supplements. But CBD is just the tip of a very large iceberg of cannabinoids that are about to sweep across the nation and the world. Hemp is a plant that has hundreds of medicinally powerful compounds within it, and each one of these has major implications in the health, wellness and beauty categories worldwide. Although CBD is traditionally the most abundant cannabinoid found in hemp, new varieties of hemp are producing other rarer cannabinoids in higher amounts. 

Cannabinol, or CBN, is a cannabinoid that you probably haven’t heard of yet, but will very soon. CBN currently is showing some incredible benefits related to sleep that seriously could shake up the multibillion-dollar sleep industry. Our company, Global Cannabinoids, is the first to produce CBN in bulk quantities for distribution to manufacturers using this unique and potent compound in various formulations related to sleep. 

Another exciting cannabinoid is cannabichromene, also known as CBC. CBC is another rare cannabinoid that could prove to be more effective as a pain reliever than any other naturally occurring cannabinoid discovered thus far. The team at Global Cannabinoids is focused on the extraction and isolation of this compound and expects to have bulk quantities available for distribution before the end of 2019. 

Cannabigerol, or CBG, is gaining in popularity at a rapid pace. This is mainly due to the fact that certain varieties of hemp can produce this cannabinoid in high amounts, which makes extracting it commercially viable. CBG produces an uplifting and almost energizing effect. This cannabinoid is being used in various formulations related to energy and alertness. Global Cannabinoids is one of the largest producers and distributors of CBG isolate and CBG-rich oils.

Full-spectrum products currently are viewed as being “more effective” due largely in part to the “entourage effect” or synergy of compounds found within a whole plant extract. More and more brands are promoting their products as full spectrum, which can be defined as having the full plant profile and would always include THC at less than 0.3%. These products tend to produce a more sustained effect and arguably are better than an isolate-based product. The problem with full-spectrum oil, however, is that it is consistently difficult to produce the exact same extract every single time since every plant is different. 

Testing at certified laboratories also is a necessary piece of the supply chain puzzle. Ensuring that your cannabinoids are free of contaminants is critical. Hemp is used in phytoremediation, which means the plant literally can suck the toxins out of the soil. Not all labs are reliable, so it’s imperative to test each sample multiple times at different labs. At Global Cannabinoids, we require a third-party test before it leaves the extraction facility. We then perform testing in house at our own lab, and then we send out once more for another third-party test. By testing our concentrates extensively, we have the most accurate information as to potency and correctly can dose each product we are formulating and manufacturing. 

The future of the hemp/CBD/cannabis industry will be the ability to recreate an experience or effect consistently every time. In order to achieve this, products will need to be made consistently, using isolated cannabinoid compounds in precise formulations that can be recreated over and over again. Global Cannabinoids is currently building the largest inventory of hemp-derived cannabinoid ingredients intended to supply the brands of the future. Combining cannabinoids and other compounds in precise formulations will be critical to the success of the industry as more and more products begin to crowd the space.  

More Blog Posts In This Series

Pharmacy of the future: Integrating SDOH to understand patient needs

Jill Regan of LexisNexis Risk Solutions Health Care examines how retail pharmacy leaders continue to respond to market changes in the new decade.

Goals pharmacies can set to improve in 2020

Cathy Kuhn highlights three core resolutions pharmacists should consider adopting.

Don’t just change — improve

Bruce Kneeland discusses how a pharmacy owner, manager or staff member can help a pharmacy improve.